Vernal keratoconjunctivitis (VKC) is a chronic and potentially sight-threatening disease. Topical corticosteroids (Cs) seem to be the only effective treatment for this condition, although severe side effects may occur owing to their prolonged use. More recently, cyclosporine (Cyc) eye drops have been reported as a valid alternative, but so far such treatment has only been successfully experimented for a short time and in small numbers of patients. The aim of our study is to evaluate the long term safety and efficacy of topical cyclosporine eye drops in children suffering from VKC. Over a period of 7 years we followed a large group of children suffering from severe VKC. They were selected to start cyclosporine eye drop treatment, because of the prompt relapse of their disease as soon as they stopped topical corticosteroids administration. All patients were followed-up in an ambulatory care assessment. A total of 156 children with VKC were treated with topical cyclosporine eye drops over a period ranging from two to seven years (mean time 3.8±1.09 years) during the seasonal relapse (range 9-66 months; mean time 24.7±10.4 months). Two formulations, at 1% and 2% (82% and 18% respectively) concentrations, of cyclosporine eye drops were made. The dosage administered was one drop in each eye from two to four times a day, depending on the severity of the disease and the season. The ocular objective scores were determined and compared every year, at the beginning and at the end of each treatment period. Blood samples were collected once a year in order to check both kidney and liver functions, as well as cyclosporine serum levels. We enrolled 156 patients (mean age 8.31±2.79 years; 116 males and 40 females) who were followed-up over a period of 7 years (156 (100%) children during the first and the second year; 138 (88.5%) patients until the third year; 90 (57.7%) until the fourth year; 32 (20.5%) until the fifth year; 10 (6.4%) until the sixth year and 2 (1.3%) until the seventh year). The ocular objective scores significantly improved (p<.OOI) over the years when comparing them at the beginning and the end of each seasonal treatment period, except for the last year. Over the treatment period, non-significant changes were recorded in terms of kidney and liver enzymatic activities and also in terms of cyclosporine serum levels. Cyclosporine eye drops, either at 1% or 2% concentrations, resulted safe and effective for long-term treatment of VKC in 156 children. The lack of significance of the score results during the seventh year can be explained by the small number of subjects treated for such a long period. A systematic ocular examination and both liver and kidney functional investigations allowed us to exclude the possibility of local or systemic side effects due to cyclosporine. If either transient or long-lasting, the occurrence of burning was referred by some of the patients treated, but none of them required to discontinue the drug. In conclusion, this is the first study showing that topical cyclosporine is easily handled even by children, with safe and effective results even when it is used over a long period of time. Our findings, though encouraging, need to be confirmed by further studies.
allergic conjunctivitis. It typically starts in the first decade of life and it usually disappears within the second decade (2) . In temperate regions such as Mediterranean areas, the severity of the disease increases during spring and summer and it decreases during fall and winter (2) (3) (4) . Giant papillae in the upper tarsal conjunctiva and/or limbal papillar hypertrophy characterize the tarsal and the bulbar forms, respectively. Corneal ulcers, evolving into permanent scars, are possible complications.
Topical drugs such as antihistamines, chromones and NSAIDs have been frequently used, but their efficacy is limited to mild or very mild forms. Topical corticosteroids (Cs) seem to be the only effective treatment for VKC, but severe side effects (for example ocular hypertension, glaucoma and cataract) have been described in association with a prolonged use of such a drug. Cyclosporine (Cyc), a calcineurin inhibitor, has been successfully employed to treat VKC as eye drop formulations, although for short periods and in small numbers of patients. In contrast to corticosteroids, cyclosporine does not produce lens changes nor does it increase intraocular pressure (5) . When it is used as a systemic drug, Cyc may induce nephrotoxicity and liver dysfunction, mainly in patients subjected to liver, kidney or heart transplantations. At the same time, Cyc could be a valid alternative for treatment of B-chronic lymphocytic leukemia, thanks to its pro-apoptotic proprieties (6) . However, the risk of malignancy increases with prolonged use ofsystemic Cyc, because of its immunosuppressive activity. By the fact that Cyc eye drops contain small amounts of the active principle, such treatment is believed to be free from side effects. To date, data on the long term efficacy and safety of eye eye drops in the treatment ofVKC are still lacking.
In the present study we evaluate the safety and efficacy of topical Cyc for the treatment of 156 patients with VKC. Cyc was used for 6 months / year (mean period: 4 years) in the study population.
Thanks to its immunosuppressive properties, Cyc is most commonly used for the prevention of organ graft rejection (4) and for the treatment of selected autoimmune disorders (uveitis, psoriasis, reumathoid arthritis, nephrosic syndrome, atopic dermatitis). Its efficacy in controlling ocular inflammation has been previously demonstrated (5) . It blocks helper T-lymphocyte proliferation and IL-2 production (7) (8) . Moreover Cyc inhibits histamine release from human mast cells and basophils and it may also reduce eosinophil recruitment in the conjunctiva through the inhibition ofIL-5 production. Cyc shows some advantages in VKC treatment because it does not provoke cataract or high intraocular pressure which are both reported after topical corticosteroid administration.
Since 1990, six clinical trials have been published on the treatment ofVKC with topical Cyc. A total of patients 151 were treated, all of whom used Cyc for just a short time (1-5, 7). Moreover, no homogeneous data rise from these studies in terms of: quality of ocular cyclosporine solutions used; quality and timing of ocular severity scores determinations; controls of biochemical parameters (such as kidney and liver functions, and blood Cyc levels). In this study we evaluated both the safety and efficacy of Cyc when it is used to treat VKC, at low concentrations and for a long period of time (7 years), via intraocular administration in a selected pediatric population.
MATERIALS AND METHODS

Patients
From 2001 to 2007 we followed-up 285 patients affected by VKC. One hundred and fifty-six out of 285 were enrolled in the study since they matched the following criteria: I) Seasonal VKC: worsening during spring-summer and improving during autumn-winter.
2) Perennial VKC: relapse of the disease during spring-summer. The active phase was defined according to the previously published score system (9);
3) Follow-up period lasting at least 2 years or 2 full seasons; 4) Lack of efficacy of the treatments with antihistamines and/or NSAIDs topically administered for at least 2 weeks.
Methods
Two preparations of cyclosporine eye drops were equally employed, depending on the personal tolerance and response: preparation I (Cyc-Prep I) [cyclosporine I%, solution of Sandimmun vial (Novartis Farma) in Hypotears (polyvinyl alcohol, Medivis)], and preparation 2 (Cyc-Prep2) [cyclosporine 2%, Sandimmun oral solution (Novartis Farma) in sterilized sunflower seed oil]. Both of these formulations had been previously tested in terms of stability (Center of Metabolic Diseases, A. Meyer Children Hospital, Florence, Italy) and sterility [Farmigea, Spa, Pisa, Italy for cyc in hypotears and Blood Center, A. Meyer Children Hospital, Florence, Italy for Cyc in sterilized sunflower seed oil (data not shown)].
Both preparations, Cyc-Prep 1 and Cyc-Prep2, still resulted sterile and stable a month after a daily use. However, we provided the patients with new eye drop phials every 3 weeks.
All the children enrolled underwent 3 visits a year -at the beginning, in the middle and at the end of the active phase of the conjunctivitis (typically between spring and autumn). At each visit the patients were evaluated by recording their objective ocular signs: conjunctival hyperaemia, papillae, giant tarsal papillae, limbal papillae (9) . A total objective score was assigned to each child which resulted from the sum of each single sign, graded as follows: 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The total score resulted from the sum of the two eyes' score and ranged between 0 and 24.
Two blood samples were collected every year: the first before starting the therapy in spring, and the second after at least 6 weeks of therapy. We determined alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and cyclosporine serum levels. The systemic blood pressure was also checked every time immediately before the blood withdrawal.
This study was approved by the Ethics Committee of A. Meyer Children Hospital, and informed consent was obtained from all individuals tested.
RESULTS
some hours after the administration of Cyc-Prep2 eye drops. The above symptoms tended to improve or even disappear after a variable period time ranging from 2 to 3 weeks. None discontinued the treatment. Topical Cs had been occasionally used by 60% of the patients, especially during the worsening of the disease. In particular, one-third of patients resorted to ocular Cs for seven-eight day cycles, 3 times a year, the other patients used ocular Cs no more than once or twice a year for 7-8 day cycles, each time. The additional employment of topical Cs led to short term relief, but did not change the longterm evolution ofVKC disease.
Creatinine blood values over 0.8 mg/dl, were found in 17 samples before starting the treatment (BTS) (2.9%; range 0.9-1.1) and in 15 samples collected during the treatment with Cyc (DTS). All these levels resulted within the normal range when controlled after 2-3 weeks.
ALT was found >60UI/L in 14 children BTS (2.4%; range 70-130) and in 16 DTS (2.7%; range 70-140). AST resulted >45UI/L in 18 patients BTS (3.0%; range 48-148) and in 12 DTS (2%; range 46-120). Three of these ALT and AST values measured, BTS and DTS, belonged to a patient suffering from TableI. Characteristics ofthe studypopulation. T=tarsal;
B=bulbar; M=mixedforms.
A total of 156 patients met the inclusion criteria. The demographics characteristics of the study population, together with the treatment periods and the preparations of cyclosporine eye drops tested, are reported in Table I .
The treatment efficacy was evaluated by performing the ocular objective scores, the drug safety by checking both kidney and liver functionalities. Moreover, Cyc blood levels were also monitored. Data on the efficacy of the treatment are reported in Fig. 1 and Table II ; the results on the drug safety are reported in Table III. In 4 patients (2.5%) an inflamed juvenile conjunctiva naevus was diagnosed (10) . A total of 131 patients (84%) referred sense of stinging or mild-to-moderate burning sensation immediately after the administration of Cyc-Prepl eye drops or (12) (13) (14) (15) . One hundred and seventy-seven patients had been treated for variable periods of time ranging from 2 weeks to 9 months (mean time 3.5 months).
Secchi and coll.( 1)treated 7 patients for 4 months and 4 patients for 9 months in an open trial. Eleven more patients underwent a blinded trial: 1 eye was treated with Cyc and the other eye received placebo. A Cyc solution at 2% (as intravenous preparation) in castor oil was administered according to this scheme: 2 drops/eye every 6 hours. Cyc blood levels were measured in 4 patients after one month of treatment and the values obtained always resulted under the lower detectable cut off established at 30 ng/ml. Bleik and colI. (2) used an unknown Cyc preparation at 2% diluted in corn oil. In 11 patients, it was administered 4 times daily for 6 weeks in a DBPC manner. Blood cyclosporine was not measured, while kidney and liver functions were always described as being within the normal range at the beginning and at the end of the study (data not shown).
In our study (4) 24 children had been treated with a 2% Cyc solution (oral suspension) in sterilized olive oil, for 4 weeks in a DB trial, and for 3 more months in an open trial, according to this scheme: I drop/eye 4 times daily. Serum ALT, AST, creatinine and Cyc blood levels were checked before, 4 weeks and 4 months after the treatment. Data were not shown, but Cyc levels were always under the lower detectable cut off established at 20 ng/ml. Gupta (12) (13) 15 ). To date, a total of 177 patients collected from different studies, have been treated for variable periods of time up to 9 months (mean time 3.5 months).
The efficacy of topical cyclosporine has been highlighted in all the clinical trials described. Cyc always resulted more effective when compared to placebo. The ocular objective scores, when detected, differed from the studies mentioned above, except for few parameters, which makes it difficult, even impossible, to compare the results.
In 6 out of 10 papers described, partial and nonhomogeneous data have been shown regarding the safety oftopical Cyc. This drug has been experimented in III patients, as results from the sum ofthe subjects treated in the different studies. In a recent open trial (18) involving 197 patents, Spadavecchia et al demonstrated the safety and efficacy of I% topical Cyc for a 4-month treatment of severe VKC cases. In agreement with that study our results show the efficacy of topical Cyc treatment in 156 patients affected by severe VCK (ocular score >9).
Moreover, this is the first paper evaluating both the safety and efficacy of Cyc eye drop treatment for such a long period of time (7 years), in children suffering from VKC. In this study a large population of 156 children was followed for a mean period of 3.8 years. They all underwent Cyc eye drop treatment for a mean period of 6.4 months every year. To date, this is the study published with the largest number of children enrolled and the longest follow-up time. Moreover, we systemically checked both kidney and liver functions in order to investigate the safety of such treatment. Serum Cyc levels were measured once a year and the blood pressure was determined twice a year. All the results obtained (steadily low Cyc serum levels and liver enzymes always within the normal range) represented that Cyc eye drops, even when used for approximately half a year (intermittently), are a safety and effective treatment forVKC.
